Although frontline maintenance treatment with fuzuloparib monotherapy produced a progression-free survival (PFS) benefit in patients with newly diagnosed advanced ovarian cancer, the addition of ...
Our top RSV content of 2025 included how nirsevimab and clesrovimab changed RSV prevention among younger patients, as well as ...
Here are the top 5 inflammation pieces of 2025; stay up-to-date with all the inflammation content from The American Journal ...
Discover the latest breakthroughs in myasthenia gravis treatment, including rozanolixizumab and nipocalimab, and insights on ...
Our content coverage from the Southeastern Educational Congress of Optometry (SECO) 2025 provided information on a mix of ...
Key Takeaways. TTP following R-CHOP is a strong prognostic factor for survival in R/R DLBCL, with shorter TTP linked to ...
The GLOVe regimen, combining glofitamab, lenalidomide, and venetoclax, shows rapid and deep responses in high-risk MCL ...
“In support to recent literature in arrhythmogenic cardiomyopathy, our cohort data showed that the protective effect of a negative genetic testing on disease progression was a stronger predictor than ...
Trump secures new pricing deals with 9 drugmakers, advancing his effort to align US drug costs with Europe and expand direct-to-consumer purchasing.
The 2025 pharmaceutical pipeline is expanding with generics, biosimilars, and new therapies, despite delays from patent ...
The FDA today approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of progressive pulmonary fibrosis (PPF ...
The top Managed Care Cast episodes explored wellness visits, weight loss drug access, neurospine care, public health policy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback